Coherus Oncology, Inc. cash flow to debt ratio of -343.40% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Coherus Oncology, Inc.'s free cash flow has decreased 577.66% from $-20.44M last year to $-138.51M, signaling decreasing performance

Coherus Oncology, Inc.'s debt to equity ratio is 0.62, which means that the company's assets are unhealthy financed, signaling financial risk.

Coherus Oncology, Inc.'s debt has increased relative to shareholder equity from -2.04 last year to 0.62 today, signaling weakened financials

Coherus Oncology, Inc. has a net cash position, so leverage is healthy.

Coherus Oncology, Inc.'s interest coverage ratio is -17.24, which means that the company struggles to meet interest obligations, signaling financial risk.

Coherus Oncology, Inc.'s profit margin has decreased (2.51K%) in the last year from 10.68% to -257.10%, signaling decreasing performance

Coherus Oncology, Inc.'s short-term assets of $206.71M exceed its short-term liabilities of $141.88M

Coherus Oncology, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Coherus Oncology, Inc.'s return on equity of -181.73%, is lower than 15.00%, indicating bad performance

Coherus Oncology, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Coherus Oncology, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Coherus Oncology, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Coherus Oncology, Inc. has negative free cash flow, indicating cash burn

Coherus Oncology, Inc.'s yearly earnings has decreased 697.37% since last year from $28.51M to $-170.29M, signaling decreasing performance

Coherus Oncology, Inc.'s yearly revenue has decreased 84.20% since last year from $266.96M to $42.17M, signaling decreasing performance

ROIC -135.38% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Coherus Oncology, Inc.'s 3-year revenue CAGR of -41.54% is negative, indicating declining revenue over the past 3 years

Coherus Oncology, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Coherus Oncology, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Coherus Oncology, Inc. has insufficient data to evaluate this check.

Coherus Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Coherus Oncology, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Coherus Oncology, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Coherus Oncology, Inc. is overvalued relative to its fair value price of -1.90 based on Earnings Fair Value model

Coherus Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Coherus Oncology, Inc. has a price-to-book ratio of 3.16x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Coherus Oncology, Inc. has a price-to-sales ratio of 3.77x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue